Education
About Us
Working with TipRanks
Follow Us
BeiGene Ltd (HK:6160)
:6160
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.31Last Year’s EPS
-1.45Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: 7.38%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record revenue growth, market leadership of BRUKINSA, and successful pipeline progress, which were only partially offset by challenges in fixed duration treatment options and rising R&D costs.Company Guidance
During BeiGene's Q4 and Full Year 2024 earnings call, the company provided comprehensive financial guidance for 2025. BeiGene anticipates revenue growth between $4.9 billion to $5.3 billion, driven by continued leadership in the U.S. BRUKINSA market and global expansion efforts. The company expects a stable pricing environment for BRUKINSA, with BRUKINSA generating significant revenue from both new and existing patients. Operating expenses are projected to be between $4.1 billion and $4.4 billion, with a focus on sustaining growth and advancing pipeline assets. Gross margins are expected to remain in the mid-80% range. BeiGene also aims to achieve GAAP operating breakeven and generate positive cash flow from operations in 2025. The guidance reflects confidence in BRUKINSA's differentiation and market position, as well as potential opportunities with their pipeline, including fixed duration combinations and BTK degraders.Record Revenue Growth
BeiGene achieved $3.8 billion in revenue for the full year 2024, marking a 55% increase compared to 2023. Q4 revenue reached $1.1 billion, with BRUKINSA contributing $828 million, representing 100% growth compared to Q4 2023.
BRUKINSA's Market Leadership
BRUKINSA became the BTKi class leader for new patient starts less than two years from first approval in CLL. In Q4, U.S. sales were $616 million, a 97% increase from the prior year.
Successful Pipeline Progress
BeiGene introduced 13 new molecular entities into the clinic in 2024, more than any of its peers, including the largest pharma companies.
Positive Financial Outlook
The company achieved positive quarterly cash flow from operations and is on track to achieve full-year GAAP operating breakeven in 2025.
Manufacturing and Infrastructure Expansion
Completion of an $800 million U.S. flagship manufacturing facility and redomiciliation to Switzerland were noted as key milestones.
---
HK:6160 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HK:6160 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | HK$151.70 | HK$159.60 | +5.21% |
| Nov 12, 2024 | HK$125.20 | HK$121.80 | -2.72% |
| Aug 27, 2024 | HK$120.90 | HK$121.80 | +0.74% |
| May 08, 2024 | HK$97.50 | HK$94.80 | -2.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BeiGene Ltd (HK:6160) report earnings?
BeiGene Ltd (HK:6160) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is BeiGene Ltd (HK:6160) earnings time?
BeiGene Ltd (HK:6160) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of BeiGene Ltd stock?
The P/E ratio of BeiGene Ltd is N/A.
What is HK:6160 EPS forecast?
HK:6160 EPS forecast for the fiscal quarter 2025 (Q1) is -0.31.
---